Sherita Cody
Payments from drug & device makers
Across 569 payments — averaging $14.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Johnson & Johnson$1K
- Alkermes, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$866
- AbbVie$748
- plus $2K from 12 others
What the payments were for
- Food & beverage$8,178100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 78 | $1,226 |
| Otsuka America Pharmaceutical, Inc. | 68 | $1,215 |
| Johnson & Johnson | 80 | $1,192 |
| Alkermes, Inc. | 60 | $1,024 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 105 | $866 |
| AbbVie | 42 | $748 |
| Teva Pharmaceuticals USA, Inc. | 60 | $696 |
| Neurocrine Biosciences, Inc. | 40 | $527 |
| Indivior Inc. | 13 | $254 |
| Vanda Pharmaceuticals Inc. | 9 | $199 |
| Sunovion Pharmaceuticals Inc. | 4 | $43 |
| E.r. Squibb & Sons, L.L.C. | 1 | $37 |
| Braeburn Inc. | 2 | $36 |
| Lilly USA, LLC | 2 | $32 |
| Noven Therapeutics, LLC | 2 | $29 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Exact Sciences | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
How this compares
$8,178 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 49 | $48,409 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 71 | $47,915 |
| JardianceEmpagliflozin | 67 | $38,982 |
| TradjentaLinagliptin | 51 | $27,237 |
| Spiriva RespimatTiotropium Bromide | 37 | $19,507 |
| Incruse ElliptaUmeclidinium Bromide | 41 | $18,069 |
| LinzessLinaclotide | 25 | $14,841 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 503 | $14,302 |
| Breo ElliptaFluticasone/Vilanterol | 33 | $13,820 |
| SymbicortBudesonide/Formoterol Fumarate | 58 | $13,512 |
| FarxigaDapagliflozin Propanediol | 17 | $12,134 |
| Spiriva HandihalerTiotropium Bromide | 20 | $10,679 |
| TrulicityDulaglutide | 11 | $9,840 |
| MyrbetriqMirabegron | 15 | $9,625 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 90 | $8,752 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $748 | $14,84125 claims |
| Lilly USA, LLCTrulicity | $32 | $9,84011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.
Other family in Akron
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.